Bexagliflozin
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för bexagliflozin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
22 hitsEfficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Xie L, Han J, Cheng Z, Liu D, Liu J, Xu C, Sun W, Li Q, Bian F, Zhang W, Chen J, Zhu Q, Thurber TK, Lock JP, Zhang B.
J Diabetes · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/1753-0407.13526Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
McMurray JJV, Solomon SD, Lock JP, Massaro JM, Zhu F, Zhou W, Skali H, Lewis EF, Freeman MW, Halvorsen YC.
Diabetes Obes Metab · meta-analysis; journal article · DOI 10.1111/dom.15394Bexagliflozin.
Giruzzi M, Worthey A.
Clin Diabetes · research-article; journal article · DOI 10.2337/cd23-0085Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M.
Expert Opin Pharmacother · meta-analysis; systematic review; journal article · DOI 10.1080/14656566.2023.2269854A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes.
Cowart K, Coon S, Carris NW.
Ann Pharmacother · review; journal article · DOI 10.1177/10600280231190443Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1683bCardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.
Frąk W, Hajdys J, Radzioch E, Szlagor M, Młynarska E, Rysz J, Franczyk B.
Biomedicines · review-article; review; journal article · DOI 10.3390/biomedicines11072085Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW.
Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.15192Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.
Hadd MJ, Bienhoff SE, Little SE, Geller S, Ogne-Stevenson J, Dupree TJ, Scott-Moncrieff JC.
J Vet Intern Med · research-article; journal article; clinical trial, veterinary · DOI 10.1111/jvim.16730Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Pasqualotto E, Figueiredo Watanabe JM, Gewehr DM, da Silva Maintinguer R, van de Sande-Lee S, de Araujo GN, Leal FS, Pinheiro CEA.
Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/dom.15051Bexagliflozin: First Approval.
Hoy SM.
Drugs · review; journal article · DOI 10.1007/s40265-023-01848-xA 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW.
Diabetes Obes Metab · randomized controlled trial; journal article · DOI 10.1111/dom.14875Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus.
Patoulias D, Dimosiari A.
Am J Cardiol · letter; meta-analysis · DOI 10.1016/j.amjcard.2022.05.005Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
Benedict SL, Mahony OM, McKee TS, Bergman PJ.
Can J Vet Res · research-article; journal articleBexagliflozin for type 2 diabetes: an overview of the data.
Azzam O, Carnagarin R, Lugo-Gavidia LM, Nolde J, Matthews VB, Schlaich MP.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2021.1959915A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Halvorsen YD, Walford G, Thurber T, Russell H, Massaro M, Freeman MW.
Diabetes Obes Metab · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13928Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans.
Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen YD, Welihinda A.
Xenobiotica · journal article · DOI 10.1080/00498254.2019.1654634A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW.
Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13833A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW.
Diabetes Obes Metab · comparative study; equivalence trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13801Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, Trescoli C, Serusclat P, Freeman MW, Halvorsen YC.
Am J Kidney Dis · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1053/j.ajkd.2019.03.417EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Zhang W, Welihinda A, Mechanic J, Ding H, Zhu L, Lu Y, Deng Z, Sheng Z, Lv B, Chen Y, Roberge JY, Seed B, Wang YX.
Pharmacol Res · journal article · DOI 10.1016/j.phrs.2011.01.001